New twice-yearly infusion for relapsing MS: ublituximab

Credibility

Interest

Key Takeaway

Ublituximab is a new twice-yearly IV medicine that reduces B cells and is approved to lower relapses in adults with relapsing forms of MS.

What They Found

Researchers developed ublituximab, a lab-made antibody that targets CD20, a protein on B cells; B cells are immune cells that can wrongly attack the nervous system in MS. The drug works by marking B cells so other immune cells remove them, a bit like tagging bad apples for sorting out of a fruit bin. After initial doses, ublituximab is given as a one-hour infusion only twice a year, which is less often than many other MS infusions. Clinical studies showed it reduced relapses and activity on MRI scans, which are pictures doctors use to see inflammation in the brain and spinal cord. The U.S. approved ublituximab in December 2022 for adults with relapsing MS types, meaning it met safety and benefit standards for those patients.

Who Should Care and Why

People with relapsing forms of MS should notice because ublituximab aims to lower relapses and slow new inflammatory damage, which can help with daily symptoms and long-term function. Caregivers may find the twice-yearly schedule easier to plan around than treatments needing monthly visits, like planning two big appointments instead of many small ones. Clinicians and nurses will care because it adds another option for patients who need stronger immune-targeting therapy or who prefer less frequent infusions. Someone worried about frequent clinic visits, travel, or time off work may find this treatment more convenient, similar to switching from frequent short trips to a couple longer trips a year. Families should still discuss individual risks, monitoring needs, and vaccine timing with their care team, because removing B cells affects the immune system.

Important Considerations

The approval is based on trials but long-term safety and how it compares directly to all other MS drugs over many years are still being studied. Removing B cells can raise the chance of infections and may affect how well vaccines work, so infection risk and vaccine timing are important considerations. Not everyone with MS is eligible; this approval is for adults with relapsing forms, so talk with your neurologist to see if it fits your health, other medicines, and life situation.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials MS Progression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Drugs often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News